99
Views
36
CrossRef citations to date
0
Altmetric
Original

Regulatory T Cells in the Control of Autoimmune Diabetes: The Case of the NOD Mouse

&
Pages 247-267 | Published online: 03 Aug 2009

REFERENCES

  • J.F. Bach, Insulin-dependent diabetes mellitus as an autoimmune disease, Endocrine Rev., 15: 516–542, 1994. [CSA]
  • J.F. Bach, Immunotherapy of type 1 diabetes: Lessons for other autoimmune diseases, Arthritis Res., 4: S3–S15, 2002. [CROSSREF]
  • C.L. Vanderlugt and S.D. Miller, Epitope spreading in immune-mediated diseases: Implications for immunotherapy, Nat. Rev. Immunol., 2: 85–95, 2002. [CSA], [CROSSREF]
  • J.F. Bach, S. Koutouzov, and P.M. Van Endert, Are there unique autoantigens triggering autoimmune diseases? Immunol. Rev., 164: 139–155, 1998. [CSA]
  • Z. Lando, D. Teitelbaum, and R. Arnon, Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE, J. Immunol., 123: 2156–2160, 1979.
  • C. Boitard, R. Yasunami, M. Dardenne, and J.F. Bach, T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice, J. Exp. Med., 169: 1669–1680, 1989. [CROSSREF]
  • A. Bendelac, C. Carnaud, C. Boitard, and J.F. Bach, Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells, J. Exp. Med., 166: 823–832, 1987. [CROSSREF]
  • P. Sempe, M.F. Richard, J.F. Bach, and C. Boitard, Evidence of CD4+ regulatory T cells in the non-obese diabetic male mouse, Diabetologia, 37: 337–343, 1994.
  • M. Dardenne, F. Lepault, A. Bendelac, and J.F. Bach, Acceleration of the onset of diabetes in NOD mice by thymectomy at weaning, Eur. J. Immunol., 19: 889–895, 1989. [CSA]
  • Y. Nishizuka and T. Sakakura, Thymus and reproduction: Sex-linked dysgenesia of the gonad after neonatal thymectomy in mice, Science, 166: 753–755, 1969.
  • M. Asano, M. Toda, N. Sakaguchi, and S. Sakaguchi, Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation, J. Exp. Med., 184: 387–396, 1996. [CROSSREF]
  • P.W. Askenase, B.J. Hayden, and R.K. Gershon, Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses, J. Exp. Med., 141: 697–702, 1975. [CROSSREF]
  • R. Yasunami and J.F. Bach, Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice, Eur. J. Immunol., 18: 481–484, 1988. [CSA]
  • B. Charlton, A. Bacelj, R.M. Slattery, and T.E. Mandel, Cyclophosphamide-induced diabetes in NOD/WEHI mice. Evidence for suppression in spontaneous autoimmune diabetes mellitus, Diabetes, 38: 441–447, 1989.
  • J. Mahiou, U. Walter, F. Lepault, F. Godeau, J.F. Bach, and L. Chatenoud, In vivo blockade of the Fas-Fas ligand pathway inhibits cyclophosphamide-induced diabetes in NOD mice, J. Autoimmun., 16: 431–440, 2001. [CSA], [CROSSREF]
  • R. Yasunami, M. Debray-Sachs, and J.F. Bach, Ontogeny of regulatory and effector T-cells in autoimmune NOD mice, In E. Shafrir (Ed.), Frontiers in Diabetes Research. Lessons from Animal Diabetes III, London: Smith-Gordon, 1990.
  • J.D. Katz, B. Wang, K. Haskins, C. Benoist, and D. Mathis, Following a diabetogenic T cell from genesis through pathogenesis, Cell, 74: 1089–1100, 1993. [CROSSREF]
  • M.O. Kurrer, S.V. Pakala, H.L. Hanson, and J.D. Katz, Beta cell apoptosis in T cell-mediated autoimmune diabetes, Proc. Natl. Acad. Sci. U.S.A., 94: 213–218, 1997. [CSA], [CROSSREF]
  • A. Gonzalez, I. Andre-Schmutz, C. Carnaud, D. Mathis, and C. Benoist, Damage control, rather than unresponsiveness, effected by protective DX5+ T cells in autoimmune diabetes, Nat. Immunol., 2: 1117–1125, 2001. [CROSSREF]
  • S. You, G. Slehoffer, S. Barriot, J.F. Bach, L. Chatenoud. Unique role of CD4+CD62L+ regulatory T cells in the control of autoimmune diabetes in TCR transgenic mice, Proc. Natl. Acad. Sci. USA., 101 Suppl 2: 14580–14585, 2004. [CSA], [CROSSREF]
  • D.J. Lenschow, K.C. Herold, L. Rhee, B. Patel, A. Koons, H.Y. Qin, E. Fuchs, B. Singh, C.B. Thompson, and J.A. Bluestone, CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes, Immunity, 5: 285–293, 1996. [CSA], [CROSSREF]
  • B. Salomon, D.J. Lenschow, L. Rhee, N. Ashourian, B. Singh, A. Sharpe, and J.A. Bluestone, B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes, Immunity, 12: 431–440, 2000. [CSA], [CROSSREF]
  • R. Tisch, B. Wang, and D.V. Serreze, Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent, J. Immunol., 163: 1178–1187, 1999.
  • D.V. Serreze, H.D. Chapman, C.M. Post, E.A. Johnson, W.L. Suarez-Pinzon, and A. Rabinovitch, Th1 to Th2 cytokine shifts in nonobese diabetic mice: Sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation, J. Immunol., 166: 1352–1359, 2001.
  • L. Chatenoud, B. Salomon, and J.A. Bluestone, Suppressor T cells—They're back and critical for regulation of autoimmunity! Immunol. Rev., 182: 149–163, 2001. [CSA], [CROSSREF]
  • F. Lepault, M.C. Gagnerault, C. Faveeuw, H. Bazin, and C. Boitard, Lack of L-selectin expression by cells transferring diabetes in NOD mice: Insights into the mechanisms involved in diabetes prevention by Mel-14 antibody treatment, Eur. J. Immunol., 25: 1502–1507, 1995. [CSA]
  • A. Herbelin, J.M. Gombert, F. Lepault, J.F. Bach, and L. Chatenoud, Mature mainstream TCR alpha beta(+)CD4(+) thymocytes expressing L-selectin mediate “active tolerance” in the nonobese diabetic mouse, J. Immunol., 161: 2620–2628, 1998.
  • F. Lepault and M.C. Gagnerault, Characterization of peripheral regulatory CD4(+) T cells that prevent diabetes onset in nonobese diabetic mice, J. Immunol., 164: 240–247, 2000.
  • R.H. Friedline, C.P. Wong, D.A. Steeber, T.F. Tedder, and R. Tisch, L-selectin is not required for T cell-mediated autoimmune diabetes, J. Immunol., 168: 2659–2666, 2002.
  • L.A. Stephens and D. Mason, CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD25− subpopulations, J. Immunol., 165: 3105–3110, 2000.
  • T. Oida, X. Zhang, M. Goto, S. Hachimura, M. Totsuka, S. Kaminogawa, and H.L. Weiner, CD4+CD25 T Cells that express latency-associated peptide on the surface suppress CD4+CD45RB high-induced colitis by a TGF-beta-dependent mechanism, J. Immunol., 470: (in press).
  • B. Hultgren, X.J. Huang, N. Dybdal, and T.A. Stewart, Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice, Diabetes, 45: 812–817, 1996.
  • O. Kanagawa, G. Xu, A. Tevaarwerk, and B.A. Vaupel, Protection of nonobese diabetic mice from diabetes by gene(s) closely linked to IFN-gamma receptor loci, J. Immunol., 164: 3919–3923, 2000.
  • M. Debray-Sachs, C. Carnaud, C. Boitard, H. Cohen, I. Gresser, P. Bedossa, and J.F. Bach, Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma, J. Autoimmun., 4: 237–248, 1991. [CROSSREF]
  • J.M. Phillips, N.M. Parish, M. Drage, and A. Cooke, Cutting edge: Interactions through the IL-10 receptor regulate autoimmune diabetes, J. Immunol., 167: 6087–6091, 2001.
  • F. Powrie, J. Carlino, M.W. Leach, S. Mauze, and R.L. Coffman, A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells, J. Exp. Med., 183: 2669–2674, 1996. [CROSSREF]
  • F. Bridoux, A. Badou, A. Saoudi, I. Bernard, E. Druet, R. Pasquier, P. Druet, and L. Pelletier, Transforming growth factor beta (TGF-beta)-dependent inhibition of T helper cell 2 (Th2)-induced autoimmunity by self-major histocompatibility complex (MHC) class II-specific, regulatory CD4(+) T cell lines, J. Exp. Med., 185: 1769–1775, 1997. [CROSSREF]
  • R. Josien, P. Douillard, C. Guillot, M. Muschen, I. Anegon, J. Chetritt, S. Menoret, C. Vignes, J.P. Soulillou, and M.C. Cuturi, A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance, J. Clin. Invest., 102: 1920–1926, 1998. [CSA]
  • A. Miller, O. Lider, A.B. Roberts, M.B. Sporn, and H.L. Weiner, Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering, Proc. Natl. Acad. Sci. U. S. A., 89: 421–425, 1992. [CSA]
  • A.M. Thornton and E.M. Shevach, CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production, J. Exp. Med., 188: 287–296, 1998. [CROSSREF]
  • T. Takahashi, Y. Kuniyasu, M. Toda, N. Sakaguchi, M. Itoh, M. Iwata, J. Shimizu, and S. Sakaguchi, Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: Induction of autoimmune disease by breaking their anergic/suppressive state, Int. Immunol., 10: 1969–1980, 1998. [CROSSREF]
  • E.M. Shevach, CD4+ CD25+ suppressor T cells: More questions than answers, Nat. Rev. Immunol., 2: 389–400, 2002. [CSA]
  • S. You, M. Belghith, S. Cobbold, MA. Alyanakian, C. Gouarin, S. Barriot, C. Garcia, H. Waldmann, J.F. Bach, L. Chatenoud, Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T cells, Diabetes (in press), 2005.
  • K. Nakamura, A. Kitani, and W. Strober, Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta, J. Exp. Med., 194: 629–644, 2001. [CROSSREF]
  • C.A. Piccirillo, J.J. Letterio, A.M. Thornton, R.S. McHugh, M. Mamura, H. Mizuhara, and E.M. Shevach, CD4(+)CD25(+) Regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness, J. Exp. Med., 196: 237–246, 2002. [CROSSREF]
  • S. Read, V. Malmstrom, and F. Powrie, Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation, J. Exp. Med., 192: 295–302, 2000. [CROSSREF]
  • T. Takahashi, T. Tagami, S. Yamazaki, T. Uede, J. Shimizu, N. Sakaguchi, T.W. Mak, and S. Sakaguchi, Immunologic self-tolerance maintained by CD25(+) CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4, J. Exp. Med., 192: 303–310, 2000. [CROSSREF]
  • E. Larger, C. Becourt, J.F. Bach, and C. Boitard, Pancreatic islet beta cells drive T cell-immune responses in the nonobese diabetic mouse model, J. Exp. Med., 181: 1635–1642, 1995. [CROSSREF]
  • N.F. Bernard, F. Ertug, and H. Margolese, High incidence of thyroiditis and anti-thyroid autoantibodies in NOD mice, Diabetes, 41: 40–46, 1992.
  • A.G. Baxter and T.E. Mandel, Hemolytic anemia in non-obese diabetic mice, Eur. J. Immunol., 21: 2051–2055, 1991.
  • A.G. Baxter, A.C. Horsfall, D. Healey, P. Ozegbe, S. Day, D.G. Williams, and A. Cooke, Mycobacteria precipitate an SLE-like syndrome in diabetes-prone NOD mice, Immunology, 83: 227–231, 1994.
  • M.S. Anderson, E.S. Venanzi, L. Klein, Z. Chen, S.P. Berzins, S.J. Turley, H. Von Boehmer, R. Bronson, A. Dierich, C. Benoist, and D. Mathis, Projection of an immunological self shadow within the thymus by the aire protein, Science, 298: 1395–1401, 2002.
  • J.M. Gombert, A. Herbelin, E. Tancrede-Bohin, M. Dy, C. Carnaud, and J.F. Bach, Early quantitative and functional deficiency of NK1(+)- like thymocytes in the NOD mouse, Eur. J. Immunol., 26: 2989–2998, 1996. [CSA]
  • C. Carnaud, J.M. Gombert, O. Donnars, H.J. Garchon, and A. Herbelin, Protection against diabetes and improved NW/NKT cell performance in NOD.NK1.1 mice congenic at the NK complex, J. Immunol., 166: 2404–2411, 2001.
  • B. Wang, Y.B. Geng, and C.R. Wang, CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes, J. Exp. Med., 194: 313–320, 2001. [CROSSREF]
  • F.D. Shi, M. Flodstrom, B. Balasa, S.H. Kim, K. Van Gunst, J.L. Strominger, S.B. Wilson, and N. Sarvetnick, Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse, Proc. Natl. Acad. Sci. U. S. A., 98: 6777–6782, 2001. [CSA], [CROSSREF]
  • A. Lehuen, O. Lantz, L. Beaudoin, V. Laloux, C. Carnaud, A. Bendelac, J.F. Bach, and R.C. Monteiro, Overexpression of natural killer T cells protects V alpha 14-J alpha 281 transgenic nonobese diabetic mice against diabetes, J. Exp. Med., 188: 1831–1839, 1998. [CROSSREF]
  • S. Hong, M.T. Wilson, I. Serizawa, L. Wu, N. Singh, O.V. Naidenko, T. Miura, T. Haba, D.C. Scherer, J. Wei, M. Kronenberg, Y. Koezuka, and L. Van Kaer, The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice, Nat. Med., 7: 1052–1056, 2001. [CSA], [CROSSREF]
  • S. Sharif, G.A. Arraeza, P. Zucker, Q.S. Mi, J. Sondhi, O.V. Naidenko, M. Kronenberg, Y. Koezuka, T.L. Delovitch, J.M. Gombert, M. Leite de Moraes, C. Gouarin, R. Zhu, A. Hameg, T. Nakayama, M. Taniguchi, F. Lepault, A. Lehuen, J.F. Bach, and A. Herbelin, Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes, Nat. Med., 7: 1057–1062, 2001. [CSA], [CROSSREF]
  • W. Savino, C. Carnaud, J.J. Luan, J.F. Bach, and M. Dardenne, Characterization of the extracellular matrix-containing giant perivascular spaces in the NOD mouse thymus, Diabetes, 42: 134–140, 1993.
  • E. Colomb, W. Savino, L. Wicker, L. Peterson, M. Dardenne, and C. Carnaud, Genetic control of giant perivascular space formation in the thymus of NOD mice, Diabetes, 45: 1535–1540, 1996.
  • W. Savino, C. Boitard, J.F. Bach, and M. Dardenne, Studies on the thymus in nonobese diabetic mouse. I. Changes in the microenvironmental compartments, Lab. Invest., 64: 405–417, 1991. [CSA]
  • J. Salaun, N. Simmenauer, P. Belo, A. Coutinho, and N.M. Le Douarin, Grafts of supplementary thymuses injected with allogeneic pancreatic islets protect nonobese diabetic mice against diabetes, Proc. Natl. Acad. Sci. U. S. A., 99: 874–877, 2002. [CSA], [CROSSREF]
  • M.J. Rapoport, A. Jaramillo, D. Zipris, A.H. Lazarus, D.V. Serreze, E.H. Leiter, P. Cyopick, J.S. Danska, and T.L. Delovitch, Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice, J. Exp. Med., 178: 87–99, 1993. [CROSSREF]
  • A.M. Yamamoto, Y. Chernajovsky, F. Lepault, O. Podhajcer, M. Feldmann, J.F. Bach, and L. Chatenoud, The activity of immunoregulatory T cells mediating active tolerance is potentiated in non obese diabetic mice mice by an IL4-based retroviral gene therapy, J. Immunol., 166: 4973–4980, 2001.
  • K.J. Pennline, E. Roque-Gaffney, and M. Monahan, Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse, Clin. Immunol. Immunopathol., 71: 169–175, 1994. [CROSSREF]
  • P. Zaccone, J. Phillips, I. Conget, R. Gomis, K. Haskins, A. Minty, K. Bendtzen, A. Cooke, and F. Nicoletti, Interleukin-13 prevents autoimmune diabetes in NOD mice, Diabetes, 48: 1522–1528, 1999.
  • R. Mueller, T. Krahl, and N. Sarvetnick, Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice, J. Exp. Med., 184: 1093–1099, 1996. [CROSSREF]
  • D.L. Kaufman, M. Clare-Salzler, J. Tian, T. Forsthuber, G.S.P. Ting, P. Robinson, M.A. Atkinson, E.E. Sercarz, A.J. Tobin, and P.V. Lehmann, Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes, Nature, 366: 69–72, 1993. [CROSSREF]
  • R. Tisch, X.D. Yang, S.M. Singer, R.S. Liblau, L. Fugger, and H.O. McDevitt, Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice, Nature, 366: 72–75, 1993. [CROSSREF]
  • J.F. Bach and L. Chatenoud, Tolerance to islet autoantigens and type I diabetes, Annu. Rev. Immunol., 19: 131–161, 2001. [CSA], [CROSSREF]
  • I. Raz, D. Elias, A. Avron, M. Tamir, M. Metzger, and I.R. Cohen, Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): A randomised, double-blind, phase II trial, Lancet, 358: 1749–1753, 2001. [CROSSREF]
  • L. Chatenoud, E. Thervet, J. Primo, and J.F. Bach, Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice, Proc. Natl. Acad. Sci. U.S.A., 91: 123–127, 1994. [CSA]
  • L. Chatenoud, CD3-specific antibody-induced active tolerance: From bench to bedside, Nat. Rev. Immunol., 3: 123–132, 2003. [CSA], [CROSSREF]
  • M. Belghith, J.A. Bluestone, S. Barriot, J. Megret, J.F. Bach, L. Chatenoud, TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes, Nat Med., 9: 1202–1208, 2003. [CSA], [CROSSREF]
  • L. Chatenoud, J. Primo, and J.F. Bach, CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice, J. Immunol., 158: 2947–2954, 1997.
  • J.A. Smith, J.Y. Tso, M.R. Clark, M.S. Cole, and J.A. Bluestone, Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy, J. Exp. Med., 185: 1413–1422, 1997. [CROSSREF]
  • K.C. Herold, W. Hagopian, J.A. Auger, E. Poumian-Ruiz, L. Taylor, D. Donaldson, S.E. Gitelman, D.M. Harlan, D.L. Xu, R.A. Zivin, and J.A. Bluestone, Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus, N. Engl. J. Med., 346: 1692–1698, 2002. [CROSSREF]
  • J.M. Gombert, E. Tancrede-Bohin, A. Hameg, M.C. Leite-de-Moraes, A. Vicari, J.F. Bach, and A. Herbelin, IL-7 reverses NK1+ T cell-defective IL-4 production in the non-obese diabetic mouse, Int. Immunol., 8: 1751–1758, 1996.
  • L.C. Harrison, M. Dempsey-Collier, D.R. Kramer, and K. Takahashi, Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes, J. Exp. Med., 184: 2167–2174, 1996. [CROSSREF]
  • A. Kukreja, G. Cost, J. Marker, C. Zhang, Z. Sun, K. Lin Su, S. Ten, M. Sanz, M. Exley, B. Wilson, S. Porcelli, and N. MacLaren, Multiple immuno-regulatory defects in type-1 diabetes, J. Clin. Invest., 109: 131–140, 2002. [CSA], [CROSSREF]
  • P.T. Lee, A. Putnam, K. Benlagha, L. Teyton, P.A. Gottlieb, and A. Bendelac, Testing the NKT cell hypothesis of human IDDM pathogenesis, J. Clin. Invest., 110: 793–800, 2002. [CSA], [CROSSREF]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.